GlassScriptPhysician profile
Kelsey Bywater
NPI 1629508403
$2,606.03
in general payments reported to CMS, 2019-2025
34 companies · $577 in 2025
The $577 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $488 · 2022: $303 · 2023: $543 · 2024: $695 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,815.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $771.76 | 2021-2025 | |
| Indivior INC. | $172.66 | 2024-2025 | Sublocade |
| Astellas Pharma US INC | $155.35 | 2021-2025 | Veozah |
| Amarin Pharma, INC. | $152.07 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $135.10 | 2021-2025 | Spravato, Xarelto |
| Amgen INC. | $127.45 | 2023-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $107.41 | 2021-2025 | |
| Glaxosmithkline, LLC. | $107.01 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $100.96 | 2021-2024 | Farxiga |
| Lilly USA, LLC | $89.31 | 2021-2025 | Mounjaro, Zepbound |
| Organon LLC | $78.30 | 2023-2025 | Nexplanon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.71 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $59.36 | 2025 | Caplyta |
| Biomerieux INC | $46.41 | 2024 | Biofire Spotfire Respiratory (R) Panel |
| Novartis Pharmaceuticals Corporation | $44.88 | 2024-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $44.12 | 2023-2024 | |
| Otsuka America Pharmaceutical, INC. | $39.76 | 2025 | Rexulti |
| Boston Scientific Corporation | $33.75 | 2023-2024 | Wavewriter Alpha Prime 16, Watchman Flx |
| Takeda Pharmaceuticals U.S.A., INC. | $28.45 | 2021-2025 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $26.31 | 2022 | |
| Abbott Laboratories | $23.49 | 2024 | Freestyle Libre 3 |
| Sanofi Pasteur INC. | $22.17 | 2023 | |
| Supernus Pharmaceuticals, INC. | $20.65 | 2022 | |
| Inspire Medical Systems, INC. | $18.89 | 2024 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $16.79 | 2023 | |
| Phathom Pharmaceuticals, INC. | $15.35 | 2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $14.97 | 2021 | |
| Allergan, INC. | $14.62 | 2021 | |
| Merck Sharp & Dohme LLC | $14.10 | 2022 | |
| Dexcom, INC. | $14.10 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.92 | 2022 | |
| Almatica Pharma LLC | $12.65 | 2021 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelsey Bywater listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.